$1.84
5.98%
Downside
Day's Volatility :6.99%
Upside
1.08%
58.7%
Downside
52 Weeks Volatility :84.77%
Upside
63.12%
Period | X T L Biopharmaceuticals Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -27.84% | 0.0% |
6 Months | -23.33% | 0.0% |
1 Year | 128.17% | 0.0% |
3 Years | -50.8% | -27.1% |
Market Capitalization | 9.9M |
Book Value | $0.01 |
Earnings Per Share (EPS) | -0.03 |
PEG Ratio | 0.0 |
Wall Street Target Price | 30.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -13.78% |
Return On Equity TTM | -13.07% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -764.0K |
Diluted Eps TTM | -0.03 |
Quarterly Earnings Growth YOY | -0.76 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 1530.43%
Sell
Neutral
Buy
X T L Biopharmaceuticals Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
X T L Biopharmaceuticals Ltd | -15.98% | -23.33% | 128.17% | -50.8% | 43.75% |
Regeneron Pharmaceuticals, Inc. | -18.16% | -14.42% | 3.52% | 34.42% | 140.62% |
Biontech Se | -5.81% | 20.18% | 11.4% | -51.12% | 460.49% |
Alnylam Pharmaceuticals, Inc. | 2.41% | 83.28% | 68.63% | 50.84% | 200.09% |
Vertex Pharmaceuticals Incorporated | 10.42% | 23.33% | 40.2% | 170.42% | 155.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
X T L Biopharmaceuticals Ltd | NA | NA | 0.0 | 0.0 | -0.13 | -0.14 | NA | 0.01 |
Regeneron Pharmaceuticals, Inc. | 20.41 | 20.41 | 1.2 | 44.89 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.1 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.13 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
X T L Biopharmaceuticals Ltd | NA | $9.9M | 43.75% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.6B | 140.62% | 20.41 | 33.61% |
Biontech Se | Buy | $25.9B | 460.49% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.1B | 200.09% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $128.9B | 155.94% | 32.84 | -4.51% |
Insights on X T L Biopharmaceuticals Ltd
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 50.8% return, outperforming this stock by 101.6%
Noked Israel Ltd
Morgan Stanley - Brokerage Accounts
Citadel Advisors Llc
Rhumbline Advisers
xtl biopharmaceuticals ltd. (nasdaq:xtlb, tase:xtlb.ta) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. the company’s lead drug candidate, hcdr1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (sle). treatments currently on the market for sle are not effective enough for most patients and some have significant side effects. robust clinical data on hcdr1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
Organization | X T L Biopharmaceuticals Ltd |
Employees | 0 |
CEO | Mr. Shlomo Spokone Shalev |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$1.84
-1.08%
Rigel Resource Acquisition Corp
$1.84
-1.08%
Fortune Rise Acquisition Corp
$1.84
-1.08%
Canada Goose Holdings Inc.
$1.84
-1.08%
J W Mays Inc
$1.84
-1.08%
American Shared Hospital Services
$1.84
-1.08%
Cambria Shareholder Yield Etf
$1.84
-1.08%
J-long Group Ltd.
$1.84
-1.08%
Cps Technologies Corp
$1.84
-1.08%